NMD Pharma reported topline Phase 2a results from SYNAPSE-CMT, a randomized, double-blind, placebo-controlled study of ignaseclant, its first-in-class skeletal muscle ClC-1 inhibitor, in 81 adults with genetically confirmed Charcot-Marie-Tooth disease types 1 or 2 across the US and Europe. The 21-day, twice-daily oral study did not meet its prespecified primary endpoint on the 6-minute walk test at day 21, but showed consistent improvement across multiple prespecified secondary endpoints, including the CMT Functional Outcome Measure, handgrip strength, fine hand function, and patient-reported outcomes on the CMT Health Index. Gains were observed during treatment and persisted to day 28 after dosing stopped. Safety was favorable with no serious adverse events reported. The company plans to accelerate development in CMT and expects additional readouts in 2026 from ongoing programs in generalized myasthenia gravis and spinal muscular atrophy.
The miss on a mobility-centric primary endpoint and strength in upper-limb and composite functional measures sets up a pivotal question: in CMT, should development pivot away from ambulation metrics toward endpoints that better capture daily function and patient priority domains? With no approved therapies in CMT and an exploratory, short-duration design, the results suggest target engagement and patient-relevant benefit, but a registrational path will hinge on choosing endpoints regulators and payers will endorse, extending treatment duration, and demonstrating durability beyond a washout window.
This matters immediately for patients who have only supportive care and for HCPs who need treatments that translate into tangible improvements in strength, dexterity, and independence. For payers, the signal in validated functional composites and disease-specific patient-reported outcomes is directionally promising, yet evidence thresholds will likely include longer-term, clinically meaningful changes, health resource utilization signals, and quality-of-life gains. For competitors in neuromuscular disease, the program reframes the focus from repairing peripheral nerve pathology to modulating muscle excitability, potentially creating a complementary or alternative route to functional improvement in a heterogeneous genetic disorder.
The readout aligns with several broader industry currents. Rare neuromuscular development is shifting toward pragmatic, mechanism-driven small molecules that can deliver rapid proof-of-concept and scalable manufacturing, in contrast to capital-intensive gene therapies. Regulators have shown openness to composite functional endpoints and disease-specific PROs in rare disorders, but alignment must be built early and supported by methodologically sound, longer-duration data. Commercial models in orphan neuromuscular diseases increasingly depend on demonstrating real-world functional benefit beyond clinic tests, pushing Medical Affairs to integrate digital performance measures, home-based assessments, and longitudinal RWE to validate day-to-day impact. Platform optionality across CMT, gMG, and SMA offers portfolio leverage, but also raises the bar to show consistency of effect across pre- and post-synaptic dysfunctions and to differentiate indications by endpoint strategy and value story.
The next phase will be defined by three execution choices: whether to elevate upper-limb function and composite measures as primary outcomes, how long to treat to reveal the full effect trajectory, and how to translate short-term signals into sustained benefit that resonates with regulators and payers. If longer-duration dosing strengthens functional deltas and confirms safety, ignaseclant could reset expectations for symptomatic yet meaningful improvement in a disease with no approved options. The strategic question now is whether NMD Pharma can convert a brief, dexterity-forward signal into a registrational program that secures regulatory buy-in and payer acceptance—and do so before the 2026 catalyst window reshapes competitive and financing dynamics in neuromuscular medicine.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
